In a recent update released to their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced 2 significant developments:
The Federal Drug Plans are now participating in the pCPA; and
The Office of the pCPA (the Office) is now fully staffed.
On January 19, 2016 the Government of Canada issued a News Release ... Read More
23
Feb2016
17
Feb2016
Ontario has released the February 2016 Summary of Changes document, which includes the addition of Hospira’s Inflectra at a price of $525.00.
Please see page 4 of the Summary of Changes document for more information regarding the clinical criteria and listing status of Inflectra.
12
Feb2016
The Alberta Price Confirmation (APC) is issued prior to an Alberta Drug Benefit List (ADBL) publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.
ADBL Effective Date
APC Tentative Issue Date
March 1, 2016
February 2, 2016
April 1, 2016
February 18, ... Read More
12
Feb2016
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews.
As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ... Read More
14
Dec2015
On November 24, 2015, Québec’s Minister of Health and Social Services, Gaétan Barrette introduced the following bill to Quebec’s National Assembly:
Bill 81: An Act to reduce the cost of certain medications covered by the basic prescription drug insurance plan by allowing calls for tender.
Bill 81 would amend the Act Respecting ... Read More
04
Dec2015
Ontario has released a summary, titled Minister’s Roundtable on Pan-Canadian Pharmacare, based on a roundtable discussion on pharmacare hosted by the Honourable Dr. Eric Hoskins, Ontario’s Minister of Health and Long-Term Care, on June 8, 2015. This summary, prepared by Health Quality Ontario, provides an overview of the discussion which ... Read More
25
Nov2015
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ... Read More
16
Oct2015
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the June 2016 “Liste des médicaments”. These meetings will be held between December 7 and December 18, 2015, inclusive.
Meetings will cover the following:
Discussion on clinical studies
Discussion ... Read More
16
Oct2015
In a recent update released on their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced two significant developments:
Québec is now participating in the pCPA; and
The Office of the pCPA (the Office) is now operational.
In Fall 2014, the Provincial/Territorial Health Ministers announced intentions for Québec’s participation in the Federation’s Health Care ... Read More
06
Oct2015
Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for ... Read More